Rare Diseases Clinical Research Network (RDCRN) Publications

Updated: October 1, 2018

RDCRN Data Management and Coordinating Center Publications

DMCC Publications

RDCRN Descriptive Publications

RDCRN Publications

RDCRN Publications, Current Grant Cycle Consortia

Advancing Research & Treatment for Frontotemporal Lobar Degeneration
Autonomic Rare Disease Clinical Research Consortium
Brain Vascular Malformations Consortium
Brittle Bone Disorders Consortium
Clinical Research in ALS & Related Disorders for Therapeutic Development
Consortium of Eosinophilic Gastrointestinal Disease Researchers
Developmental Synaptopathies Consortium
Dystonia Coalition
Genetic Disorders of Mucociliary Clearance
Inherited Neuropathies Consortium
Lysosomal Disease Network
Nephrotic Syndrome Rare Disease Clinical Research Network
North American Mitochondrial Diseases Consortium
Porphyrias Consortium
Primary Immune Deficiency Treatment Consortium
Rare Kidney Stone Consortium
Rare Lung Diseases Consortium
Rett Syndrome, MECP2 Duplications, and Rett-related Disorders Consortium
Sterol and Isoprenoid Diseases Consortium
Urea Cycle Disorders Consortium
Vasculitis Clinical Research Consortium

Resources are listed by consortium and publication type and sorted by date. JAMA Style.
Send any updates to Cameron Hainline at Cameron.Hainline@epi.usf.edu
RDCRN Publications, Previous Grant Cycle Consortia

Angelman, Rett, and Prader-Willi Syndromes Consortium
Bone Marrow Failure Consortium
Cholestatic Liver Disease Consortium
Chronic Graft Versus Host Disease Consortium
Clinical Research Consortium for Spinocerebellar Ataxias
Consortium for Clinical Investigation of Neurologic Channelopathies
Rare Genetic Steroid Disorders
Rare Thrombotic Diseases
Salivary Gland Carcinomas Consortium
RDCRN Data Management and Coordinating Center Publications

Book Chapters


Abstracts Presented at Conferences
1. Krischer J. Data collection and analysis from multiple research sites: The Rare Diseases Clinical Research Network. Paper presented at: International Conference on Rare Diseases & Orphan Drugs; February 16, 2005; Stockholm, Sweden.


23. Williams M, Krischer J. Enhancements to the Rare Diseases Clinical Research Network Contact Registry, Poster presented at: Lysosomal Disease Network, 14th Annual WORLD Symposium; Feb. 5-9, 2018; San Diego, CA. https://doi.org/10.1016/j.ymgme.2017.12.410


Conference Proceedings


17. Lee HS. (2016) A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis. Poster presentation at the LAM Foundation/International Research Conference, Cincinnati, OH.


Journal Articles


RDCRN Descriptive Publications

Conference Proceedings


Journal Articles


Advancing Research & Treatment for Frontotemporal Lobar Degeneration

Journal Articles


**Autonomic Rare Diseases Clinical Research Consortium**

**Book Chapters**


Journal Articles


10. Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. Sep 1 2009;120(9):725-734. PMID: 9687359, PMCID: PMC2758650


supine hypertension. *J Neurol.* 2017;264(8):1567-1582. PMID: 28050656, PMCID: PMC5533816


**Brain Vascular Malformation Consortium**

**Book Chapters**


Abstracted Presented at Conferences

1. Khan Y, Hart B, Morrison L. CCM in Hispanic children in New Mexico Paper presented at: 2nd Conference on Clinical Research for Rare Diseases; September 21, 2010; Washington, DC.


Conference Proceedings


Journal Articles


5. Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion


43. Lo WD, Kumar R. Arterial Ischemic Stroke in Children and Young Adults. Continuum (Minneapolis, Minn). 2017;23(1, Cerebrovascular Disease):158-180. PMID: 28157749


Brittle Bone Disorders Consortium

Abstracts


Journal Articles


Clinical Research in ALS & Related Disorders for Therapeutic Development

Journal Articles


**Consortium of Eosinophilic Gastrointestinal Disease Researchers**

**Abstracts**


**Book Chapters**


**Journal Articles**

2. Cianferoni A, Spergel JM, Muir A. Recent advances in the pathological understanding of eosinophilic esophagitis. Expert review of gastroenterology & hepatology. 2015;9(12):1501-1510. PMID: 26470602, PMCID: PMC4943572


28. Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count


55. Philpott H, Dellon E. Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. *Asia Pacific allergy*. 2018;8(2):e20. PMID: 29732296, PMCID: PMC5931927


Developmental Synaptopathies Consortium

Journal Articles


**Dystonia Coalition**

**Abstracts Presented at Conferences**


4. Rosen A, Jinnah HA. An innovative infrastructure for common consortium challenges. Poster presented at: Conference on Clinical Research for Rare Diseases; September 21, 2010; Bethesda, MD.


17. Prudente C, Pardo C, Jinnah H. Neuropathology of primary cervical dystonia. Paper presented at: Division Students Advisory Council (DSAC) Symposium 2012; Atlanta, GA.


**Journal Articles**


**Genetic Disorders of Mucociliary Clearance**

**Book Chapters**


**Abstracts Presented at Conferences**


Journal Articles


**Inherited Neuropathies Consortium**

**Book Chapters**


Abstracts Presented at Conferences


Conference Proceedings


Journal Articles


Norton N, Robertson PD, Rieder MJ, Zuchner S, Rampersaud E, Martin E, Li D, Nickerson DA, Hershberger RE. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the


89. Burns J, Menezes M, Finkel RS, et al. Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-


97. Lewis RA, McDermott MP, Herrmann DN, et al. High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A: Results of a Randomized, Double-Masked, Controlled Trial. JAMA neurology. Aug 1 2013;70(8):981-987. PMID: 23797954, PMCID: PMC3752369


mutations in riboflavin transporter RFVT2. *Brain*. Jan 2014;137(Pt 1):44-56. PMID: 24253200,
PMCID: PMC3891447

118. Laura M, Hutton EJ, Blake J, et al. Pain and small fiber function in charcot-marie-tooth disease
type 1A. *Muscle Nerve*. Jan 7 2014. PMID: 24395492

119. Mudge AJ, Bau KV, Purcell LN, et al. Normative reference values for lower limb joint range,
2014;23(1):15-25. PMID: 23852035

120. Synofzik M, Gonzalez MA, Lourenco CM, et al. PNPLA6 mutations cause Boucher-Neuhauser
and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. *Brain*. Jan
2014;137(Pt 1):69-77. PMID: 24355708, PMCID: PMC3891450

121. Esteves T, Durr A, Mundwiller E, et al. Loss of association of REEP2 with membranes leads to
PMCID: PMC3928657


123. Fischmann A, Morrow JM, Sinclair CD, et al. Improved anatomical reproducibility in
PMID: 24123788

ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation.
PMC3995328

PMCID: PMC4305331

Neurogenet*. Jun 2 2014;1-5. PMID: 24830919, PMCID: PMC4254366

127. Caballero Oteyza A, Battaloglu E, Ocek L, et al. Motor protein mutations cause a new form of
PMCID: PMC4105256

Radiol*. Jul 2014;24(7):1610-1620. PMID: 24748539, PMCID: PMC4046083

129. Johnson NE, Sowden J, Dilek N, et al. Prospective Study of Muscle Cramps in Charcot-Marie-


134. Hershey LA, Perlmutter JS. Smoking and Parkinson disease: where there is smoke there may not be fire. *Neurology*. Oct 14 2014;83(16):1392-1393. PMID: 25217061


Lysosomal Disease Network

Book Chapters


Abstracts Presented at Conferences


10. Schiffman R. The natural history of mucolipidosis type IV. Paper presented at: Lysosomal Disease Network's WORLD Symposium; February 8-10, 2012; San Diego, CA.


12. Polgreen LE, Miller BS. Preliminary data on the growth impact and safety of human growth hormone treatment in children with Hurler and Hunter syndromes. Poster presented at: Lysosomal Disease Network's WORLD Symposium; February 8-10, 2012; San Diego, CA.


17. Utz JR CT, Sorgen PJ, Whitley CB. Metabolomic study of CSF and serum markers in infantile and juvenile gangliosidosis diseases. Lysosomal Disease Network's 10th annual WORLD Symposium; February 11-13, 2014; San Diego, CA.
18. Utz JR SP, Crutcher T, Whitley CB. Screening for CSF and serum biomarkers in infantile and juvenile gangliosidosis diseases. Lysosomal Disease Network’s 10th annual WORLD Symposium; February 11-13, 2014; San Diego, CA.

19. Utz JR WC. Eradication of inhibitors to enzyme replacement therapy in Hunter syndrome patient using non-cytotoxic, non-immunosuppressing regimen. Lysosomal Disease Network’s 10th annual WORLD Symposium; February 11-13, 2014; San Diego, CA.

20. JR U. Non-cytotoxic, non-immunosuppressing approach to tolerance induction during ERT treatment. FDA Workshop on Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction; June 9, 2014; Silver Spring, MD.

21. Utz JR CT, Schneider J, Whitley CB. Biomarkers of inflammation in CSF and serum of infantile and juvenile gangliosidoses. American College of Medical Genetics and Genomics Annual Meeting; March 24-28, 2015; Salt Lake City, UT.

22. Schneider J RK, Whitley CB, Utz JR. Prevalence of hypothyroidism in adult patients with Pompe disease. Lysosomal Disease Network’s 11th annual WORLD Symposium; February 10-12, 2015; Orlando, FL.

Conference Proceedings


**Journal Articles**


lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data. *J. Inherit. Metab. Dis.* Oct 2011;34(5):1075-1081. PMID: 21556831, PMCID: PMC3174318


89. Stenger EO, Kazi Z, Lisi E, Gambello MJ, Kishnani P. Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained


Nephrotic Syndrome Rare Disease Clinical Research Network

Abstracts Presented at Conferences


3. Barisoni L. Overview of the pathology of minimal change disease and focal segmental glomerulosclerosis. Paper presented at: ISN (International Society of Nephrology) Update Course in Nephrology; December 9-12, 2011; Dubai, UAE.


15. Gipson D. Patient Reported Outcomes in Nephrotic Syndrome. Paper presented at: Rare Disease Clinical Research Network (RDCRN) Steering Committee Meeting; October 2, 2013; Rockville, MD.

16. Barisoni L. Molecular Diagnosis and Classification of FSGS. Paper presented at: American Society of Nephrology Kidney Week; November 5-10, 2013; Atlanta, GA.


Journal Articles


**North American Mitochondrial Diseases Consortium**

**Journal Articles**


**Porphyrias Consortium**

**Book Chapters**


Abstracts Presented at Conferences

1. Anderson K. CYP1A2*1F and GSTM1 Alleles Are Associated with Susceptibility to Porphyria Cutanea Tarda. Poster presented at: International Porphyrins & Porphyrias Meeting; April 2011; Cardiff, Wales.


7. Desnick RJ. The Porphyrias: Cardinal Signs and Diagnosis/Treatment. Paper presented at: American College of Medical Genetics Annual Clinical Genetics Meeting; March 31, 2012; Charlotte, NC.


Conference Proceedings


Journal Articles


13. Boynton TO, Gerdes S, Craven SH, Neidle EL, Phillips JD, Dailey HA. Discovery of a gene involved in a third bacterial protoporphyrinogen oxidase activity through comparative genomic analysis


Special Projects


Primary Immune Deficiency Treatment Consortium

Journal Articles


Rare Kidney Stone Consortium

Book Chapters


Abstracts Presented at Conferences


24. Edvardsson V. Rare causes of kidney stones and kidney failure: focus on APRT deficiency and 2,8-dihydroxyadeninuria. Paper presented at: Symposium on Rare Disease, Annual Meeting of the Icelandic Medical Association; January, 2012; Reykjavic, Iceland.


27. Lieske J. Hypertension and Urolithiasis. Paper presented at: 12th International Symposium on Urolithiasis; May, 2012; Ouro Preto, Brazil.


33. Lieske J. Primary hyperoxaluria: not such a rare disease? Paper presented at: Research on Calculous Kinetics Society Session at the American Urological Association Meeting; May, May 2012; Atlanta, GA.


42. Milliner D. Crystal nephropathies and chameleons. Paper presented at: 8th Uruguayan Congress of Nephrology; September, 2012; Montevideo, Uruguay.


44. Edvardsson VO, Hardarson S, Palsson R. Renal histopathological findings in patients with 2,8-dihydroxyadeninuria. Paper presented at: European Society For Pediatric Nephrology; September, 2012; Krakow, Poland.

45. Edvardsson V, Agustsdottir I, Palsson R. Childhood presentation and renal outcome of APRT deficiency (2,8-Dihydroxyadeninuria) in Iceland. Paper presented at: European Society For Pediatric Nephrology, 45th Annual Meeting; September, 2012; Krakow, Poland.

47. Edvardsson V. Clinical features and long-term renal outcome of Islandic patients with APRT deficiency and 2,8-dihydroxyadeninuria. Paper presented at: 11th Congress of the European Society of Internal Medicine; October, 2012; Madrid, Spain.


Journal Articles


64. Lieske JC, Turner ST, Edeh SN, Ware EB, Kardia SL, Smith JA. Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. *Journal of Nephrology*. Feb 2016;29(1):45-51. PMID: 25963767, PMCID: PMC4643420


**Rare Lung Diseases Consortium**

**Book Chapters**

Journal Articles


Rett Syndrome, MECP2 Duplication, and Rett-related Disorders Consortium

Book Chapters

Abstracts Presented at Conferences


Journal Articles


**Urea Cycle Disorders Consortium**

**Abstracts Presented at Conferences**


5. Tuchman M. Setting up Multi-Institutional Network Research in Rare Diseases: The Urea Cycle Consortium. Paper presented at: Society for Inherited Metabolic Disorders Meeting; March, 2008; Asilomar, CA


7. Lichter-Konecki U. A Rare Disease Clinical Research Consortium for the collaborative investigation of UCDs Paper presented at: Pediatric Academic Societies Annual Meeting; May, 2009; Baltimore, MD.


22. Ludwig W, Ellenbogan A, Gropman A. MFiber Tracts in the Corpus Callosum Correlate with Scores on Behavioral Tasks and Glutamine Levels in Patients with OTCD, initial study (selected


**Conference Proceedings**


Journal Articles


**Vasculitis Clinical Research Consortium**

**Book Chapters**


**Abstracts Presented at Conferences**


Journal Articles


35. Herlyn K, Hellmich B, Seo P, Merkel PA. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. *Arthritis Care Res (Hoboken)*. Nov 2010;62(11):1639-1645. PMID: 20556814, PMCID: PMC3123033


64. Espy C, Morelle W, Kavian N, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). *Arthritis Rheum.* Jul 2011;63(7):2105-2115. PMID: 21437874


RDCRN Publications, Previous Partners

Angelman, Rett, and Prader-Willi Syndromes Consortium

Bone Marrow Failure Consortium

Cholestatic Liver Disease Consortium

Clinical Research Consortium for Spinocerebellar Ataxias

Consortium for Clinical Investigation of Neurologic Channelopathies

Rare Genetic Steroid Disorders

Rare Thrombotic Diseases

Salivary Gland Carcinomas Consortium
Angelman, Rett, and Prader-Willi Syndromes Consortium

Book Chapters

Abstracts Presented at Conferences


Driscoll D. Overview of Prader-Willi syndrome. Paper presented at: Prader-Willi Syndrome Association (USA) National Meeting; July, 2008; Milwaukee, WI.

Dykens EM. Effects of growth hormone treatment on young children with Prader-Willi syndrome. Paper presented at: 30th Annual Scientific Conference of the Prader-Willi Syndrome; July, 2008; Milwaukee, WI.

Miller JL, Driscoll DJ. Changes in head circumference with growth hormone therapy in individuals with PWS. Paper presented at: Prader-Willi Syndrome Association Meeting; July, 2008; Milwaukee, WI.


31. Cassidy SB, McCandless SE, Driscoll DJ, Schwartz S. Do some people with severe Prader-Willi syndrome have two microdeletion syndromes? Paper presented at: David Smith Meeting; August, 2008; Greenwood, SC.


35. Butler MG, Kibiryeva N, Fischer W, Bittel DC. High resolution array comparative genomic hybridization (aCGH) in individuals with Prader-Willi syndrome. Paper presented at: KUMC Faculty Research Day and Poster Session; November 6, 2008; Kansas City, KS.


Journal Articles


72. Meng L, Person RE, Beaudet AL. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. *Hum. Mol. Genet.* Jul 1 2012;21(13):3001-3012. PMID: 22493002, PMCID: PMC3465693


**Special Projects**


**Bone Marrow Failure Consortium**

**Abstracts Presented at Conferences**


5. Bai F, Zou J, Wei S, Painter J, Blaskovich M, Sebti S, Loughran T, Epling-Burnette P. Th2 polarization induced by the farnesyltransferase inhibitor Tipifarnib (Zarnestra, R115777) through suppression of t-bet. Paper presented at: American Society of Hematology; December 8-11, 2007; Atlanta, GA.


Journal Articles


**Cholestatic Liver Disease Consortium**

**Abstracts Presented at Conferences**


Conference Proceedings

Journal Articles


**Chronic Graft Versus Host Disease Consortium**

**Conference Proceedings**


**Journal Articles**


**Clinical Research Consortium for Spinocerebellar Ataxias**

**Book Chapters**


**Abstracts Presented at Conferences**


Journal Articles


Consortium for Clinical Investigation of Neurologic Channelopathies

Abstracts Presented at Conferences


secondary outcomes show improvement in symptoms and signs of myotonia. Paper presented at: American Academy of Neurology; April 26, 2012; New Orleans, LA.

Journal Articles


Rare Genetic Steroid Disorders

Journal Articles


Rare Thrombotic Diseases Consortium

Journal Articles


**Salivary Gland Carcinomas Consortium**

**Journal Articles**


20. Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. *Cancer*. Aug 15 2012;118(16):3945-3953. PMID: 22179977, PMCID: PMC3412946


